View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch

IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch Reiterating timelines for FDA submission in 2025Transplant clinical trial has attracted leading transplant hospitalsBooked first revenue from first-generation GraftAssureIQ research-use-only kits; began shipping second generation kits in June NASHVILLE, Tenn., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its second quarter results: Fellow shareholders, We are closer than we have ever been to deli...

 PRESS RELEASE

Pennant Reports Second Quarter 2025 Results

Pennant Reports Second Quarter 2025 Results Conference Call and Webcast scheduled for tomorrow, August 7, 2025 at 10:00 am MT EAGLE, Idaho, Aug. 06, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, today announced its operating results, reporting GAAP diluted earnings per share of $0.20 for the second quarter of 2025. Pennant also reported adjusted diluted earnings per share of $0.27 for the quarter(1). Second Quarter Highlights Total revenue for the second quarter w...

 PRESS RELEASE

iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Att...

iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference NASHVILLE, Tenn., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced that it will report second quarter 2025 financial results after the market closes on Monday, August 11, 2025. iMDx will host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the followin...

 PRESS RELEASE

IMDX World Transplant Congress Late-Breaking Data Potentially Sets New...

IMDX World Transplant Congress Late-Breaking Data Potentially Sets New Bar for Predicting Graft Rejection in Kidney Transplant Patients iMDx first dd-PCR assay to combine relative and absolute measurements of dd-cfDNA into single combined scoreData show significantly improved positive predictive value (PPV) for graft rejection, which potentially broadens clinical utility for dd-cfDNA with fewer false positives, further reducing unnecessary invasive biopsies for patientsiMDx expects to evaluate combined score in ongoing FDA study (NCT07060716)iMDx will be exhibiting at Booth #324 at the Worl...

 PRESS RELEASE

iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testin...

iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant Patients on August 15, 2025 NASHVILLE, Tenn., July 28, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced that it will host a virtual key opinion leader (KOL) event on Friday, August 15, 2025 at 4:00 PM ET featuring Anthony Langone, MD (Associate Professor of Medicine, Division of Nephrology and Hypertension, Vanderbilt University). To register, Dr. Langone, who serves as the national principal investigator (NPI) for iMDx’s ongoing kidney transplant...

 PRESS RELEASE

Pennant Announces Second Quarter 2025 Earnings Release and Call

Pennant Announces Second Quarter 2025 Earnings Release and Call EAGLE, Idaho, July 22, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of operating subsidiaries that provide home health, hospice and senior living services, announced today that it expects to issue its second quarter 2025 financial results on Wednesday, August 6, 2025. Pennant invites current and prospective investors to tune into a live webcast to be held the following day, Thursday, August 7, 2025, at 10:00 a.m. Mountain Time (12:00 p.m. Eastern Time), during which Pennant’s management...

 PRESS RELEASE

Pennant Announces Home Health Acquisition in Southern California

Pennant Announces Home Health Acquisition in Southern California EAGLE, Idaho, July 01, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, announces the acquisition of a premier home health agency, GrandCare Health Services. The newly acquired agency, to be known as GrandCare Home Health, provides services in Los Angeles, Orange, Riverside and San Diego counties in California, and broadens Pennant’s service area in the region. “We are happy to welcome GrandCa...

 PRESS RELEASE

iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection T...

iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing Study indicates iMDx flagship technology’s equivalence with commercially available dd-cfDNA test kitsHead-to-head comparison of iMDx’s digital PCR-based test kits with NGS kits shows consistent results in 96 transplant patientsData was presented at the European Renal Association (ERA) 2025Extended data to be presented at the European Society of Organ Transplantation (ESOT) Congress in London, June 29 – July 2Upcoming National Principal Investigator and Key Opinion Leader call planned NASHVILLE, Tenn., June 23, 20...

 PRESS RELEASE

Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Mo...

Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville New name aligns with mission to deliver precision biomarker-based testing for both transplant and oncology careiMDx sponsoring GraftAssureIQ™ research-use-only kits at transplant labs globallyExhibiting at European Society of Organ Transplantation (ESOT) conference in London, June 29 – July 2, 2025 NASHVILLE, Tenn., June 17, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (“iMDx” or the “Company”), (Nasdaq: IMDX), formerly known as Oncocyte Corporation (Nasdaq: OCX), has anno...

 PRESS RELEASE

Medicare Boosts Reimbursement for Oncocyte’s Flagship Technology

Medicare Boosts Reimbursement for Oncocyte’s Flagship Technology New price of $2,753 for the GraftAssureCore™ assay increases total addressable market size and margin opportunityBrings pricing in line with existing competitive technologyExpands market appeal for prospective FDA-cleared kitted product at transplant centers IRVINE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a diagnostics technology company, today provided a positive update on pricing for its next-generation lab-developed test (LDT), GraftAssureCore. The new reimbursement rate strengthens the co...

 PRESS RELEASE

The Pennant Group Appoints Suzanne Snapper as Director

The Pennant Group Appoints Suzanne Snapper as Director EAGLE, Idaho, May 16, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, today announced the appointment of Suzanne D. Snapper to its board of directors following her election by a vote of shareholders in connection with the Company’s annual shareholder meeting. Ms. Snapper is the Chief Financial Officer of the Ensign Group, Inc. (“Ensign”) (NASDAQ: ENSG), a leading publicly-traded provider of skilled nursing services...

 PRESS RELEASE

Oncocyte Reports Q1 2025 Results and Business Progress

Oncocyte Reports Q1 2025 Results and Business Progress Q1 2025 pharma services revenue of $2.1 million, at 62% gross marginThree of the top 10 U.S. transplant centers expected to participate in clinical trialTen globally leading transplant hospitals are now using our GraftAssure research-use-only kitsTo reflect our larger market opportunity, we plan to rename the company in Q2 IRVINE, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its first quarter ...

 PRESS RELEASE

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

Oncocyte to Release First Quarter 2025 Results on May 12, 2025 IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 12, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: . An archived replay will be available after the c...

 PRESS RELEASE

Pennant Reports First Quarter 2025 Results

Pennant Reports First Quarter 2025 Results Conference Call and Webcast scheduled for tomorrow, May 7, 2025 at 10:00 am MT EAGLE, Idaho, May 06, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, today announced its operating results, reporting GAAP diluted earnings per share of $0.22 for the first quarter of 2025. Pennant also reported adjusted diluted earnings per share of $0.27 for the quarter(1). First Quarter Highlights Total revenue for the first q...

 PRESS RELEASE

Oncocyte Provides Positive Update on Clinical Trial Progress

Oncocyte Provides Positive Update on Clinical Trial Progress Central Institutional Review Board approved, final preparatory steps underway at first transplant centersThree of the top 10 U.S. transplant centers expected to participate in trialNearly 10% of annual U.S. transplant volume represented in trial site interestPreparing for final Q-sub FDA meeting ahead of clinical validation IRVINE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today provided a positive update on its substantial progress toward initiating its...

 PRESS RELEASE

Oncocyte’s Proprietary Assay Demonstrates Long-Term Clinical Validity

Oncocyte’s Proprietary Assay Demonstrates Long-Term Clinical Validity Transplantation Direct publication uses assay to identify rejection in patients up to 13 years post-transplant Robust data set of 131 patients with 151 kidney biopsies enrolled over four years at Charité University in BerlinSupports market expansion for testing of high-risk patient populationNew findings advance understanding of the biology of organ rejection IRVINE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced the publicatio...

 PRESS RELEASE

Pennant Announces First Quarter 2025 Earnings Release and Call

Pennant Announces First Quarter 2025 Earnings Release and Call EAGLE, Idaho, April 21, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of operating subsidiaries that provide home health, hospice and senior living services, announced today that it expects to issue its first quarter 2025 financial results on Tuesday, May 6, 2025. Pennant invites current and prospective investors to tune into a live webcast to be held the following day, Wednesday, May 7, 2025, at 10:00 a.m. Mountain Time (12:00 p.m. Eastern Time), during which Pennant’s management will di...

 PRESS RELEASE

Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conf...

Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference IRVINE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend the 24th Annual Needham Virtual Healthcare Conference, taking place from April 7-10, 2025. In addition, CEO Josh Riggs will participate in a fireside chat at the conference. During the event, Josh and Andrea will discuss Oncocyte’s innovative diagnostic technologies and will highlight...

 PRESS RELEASE

Pennant Expands Portfolio with Acquisition of Senior Living Community ...

Pennant Expands Portfolio with Acquisition of Senior Living Community in Arizona EAGLE, Idaho, April 01, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, announces the acquisition of the real estate and operations of an established senior living community in Arizona. The newly acquired community offers assisted living and memory care services, and increases Pennant’s Arizona operations by 128 units. “This acquisition aligns with our mission to provide lif...

 PRESS RELEASE

Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts

Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 millionGraftAssure RUO assay launched July 2024Signed strategic partner and investor, Bio-Rad LaboratoriesFully funded clinical kitted product development with $50+ million in equity raisesAdvanced science in transplant; achieved Medicare claims expansion IRVINE, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its four...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch